Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2012 23:31 ET | Source: Immune Pharmaceuticals Inc

EpiCept to Raise $2 Million in Registered Direct Offering

EpiCept to Raise $2 Million in Registered Direct Offering TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and...
February 08, 2012 17:24 ET | Source: Immune Pharmaceuticals Inc

EpiCept to Present at the 14th Annual BIO CEO & Investor Conference

EpiCept to Present at the 14th Annual BIO CEO & Investor Conference TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm...
February 07, 2012 00:01 ET | Source: Immune Pharmaceuticals Inc

EpiCept Files for AmiKet™ Fast Track Designation

EpiCept Files for AmiKet™ Fast Track Designation TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX:...
January 24, 2012 14:05 ET | Source: Immune Pharmaceuticals Inc

EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include Evaluation of Potential Sale Transactions

EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include Evaluation of Potential Sale Transactions TARRYTOWN, N.Y.--(BUSINESS...
January 23, 2012 00:02 ET | Source: Immune Pharmaceuticals Inc

EpiCept Corporation Receives Finalized FDA Guidance for AmiKet™ Phase III CIPN Program and Regulatory Strategy

EpiCept Corporation Receives Finalized FDA Guidance for AmiKet™ Phase III CIPN Program and Regulatory Strategy Clear Pathway for NDA Filing Identified; Fast Track Application Encouraged TARRYTOWN,...
January 09, 2012 17:03 ET | Source: Immune Pharmaceuticals Inc

EpiCept Corporation Reduces Exercise Price and Extends Expiration Date of June 2010 Series B Warrants

EpiCept Corporation Reduces Exercise Price and Extends Expiration Date of June 2010 Series B Warrants TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept...
January 09, 2012 00:02 ET | Source: Immune Pharmaceuticals Inc

EpiCept Corporation Engages SunTrust Robinson Humphrey to Advise on Strategy to Maximize AmiKet™ Potential

EpiCept Corporation Engages SunTrust Robinson Humphrey to Advise on Strategy to Maximize AmiKet™ Potential TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))--...
January 05, 2012 17:02 ET | Source: Immune Pharmaceuticals Inc

EpiCept to Present at Two Upcoming Industry Conferences

EpiCept to Present at Two Upcoming Industry Conferences TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and...
January 05, 2012 00:03 ET | Source: Immune Pharmaceuticals Inc

EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman of the Board

EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman of the Board TARRYTOWN, N.Y. (January 5, 2012) – EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today...
December 23, 2011 00:02 ET | Source: Immune Pharmaceuticals Inc

EpiCept Corporation Receives FDA Permission to Initiate AmiKet™ Phase III Clinical Development

EpiCept Corporation Receives FDA Permission to Initiate AmiKet™ Phase III Clinical Development TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept...